Domicilium Real Estate Fund III LP 3

3 · Eloxx Pharmaceuticals, Inc. · Filed May 4, 2026

Form 3

Period: 2026-04-28

10% Owner

Holdings

Common Stock, $0.01 par value
[F1]
(indirect: See footnote)
1,250,000
Common Stock, $0.01 par value
[F2]
(indirect: See footnote)
157,138
Pre-funded Warrant
[F3][F1]
(indirect: See footnote)
Exercise: $0.01→ Common Stock, $0.01 par value (1,372,652 underlying)
Pre-funded Warrant
[F3][F2]
(indirect: See footnote)
Exercise: $0.01→ Common Stock, $0.01 par value (20,841,782 underlying)

Footnotes (3)

[F1]The securities are owned directly by Domicilium Real Estate Fund III LP (the "Fund") and may be deemed to be indirectly beneficially owned by (i) Domicilium Capital Partners LLC, ("Domicilium") the investment adviser to the Fund, (ii) Domicilium Real Estate Fund III GP LLC (the "General Partner"), the general partner of the Fund, and (ii) Daniel Simon, the managing member of Domicilium and the General Partner.
[F2]The securities are owned by various entities and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to such entities and (ii) Daniel Simon, the managing member of Domicilium.
[F3]The pre-funded warrants to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.

Signature

Domicilium Real Estate Fund III LP, By: Domicilium Real Estate Fund III GP LLC, its General Partner, By: /s/ Daniel Simon, Managing Member|2026-05-04

Documents

1 file